How much does Retisert cost?

Pricing for Retisert varies by insurance plan, dose, and pharmacy. Our database does not show a fixed cost because prices change faster than we can verify. For current pharmacy prices, check your insurance's formulary tier (in the prior-authorization section), use the GoodRx or Cost Plus Drugs deep links on this page, or ask your pharmacist to run a test claim. If a copay card is listed, it usually drops the out-of-pocket significantly for commercial insurance.

Does Retisert need prior authorization?

Retisert appears on 1 payer formulary in our database. PA requirements vary by payer — see the prior-authorization table on this page for specifics. In general, specialty and brand-name drugs are more likely to require PA than generic equivalents.

Is there a copay card or patient assistance program for Retisert?

We haven't verified an active copay card or PAP for Retisert in our current data. Check NeedyMeds or RxAssist for independent directories, or submit what you find via our "Report a broken link" form.

What is Retisert used to treat?

Retisert (generic: Fluocinolone Acetonide) is indicated for Uveitis, Chorioretinitis, Disseminated Chorioretinitis. Click any condition name on this page for more detail.

Does Retisert have a generic version?

The generic name for Retisert is Fluocinolone Acetonide. Whether a generic is currently available depends on patent status — check the FDA Orange Book or ask your pharmacist. Generics are often substantially cheaper than brand-name drugs.

Retisert

Generic: Fluocinolone Acetonide

Data may be stale·Apr 23, 2026

Manufacturer: Bausch and Lomb
NDC: 24208-416
RxCUI: 1191323
Route: INTRAVITREAL
ICD-10 indication: H30.10

Affordability Check

How much will you actually pay for Retisert?

In 30 seconds, see every legitimate way to afford Retisert — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Retisert

What is this medication? Retisert is a prescription corticosteroid medication provided as a small surgical implant that is placed inside the eye. It is specifically designed to treat a condition known as chronic non-infectious uveitis that affects the posterior segment, or the back portion, of the eye. This inflammatory condition can cause vision loss if left untreated, and the implant helps manage the swelling and irritation that occurs within the ocular tissues.

The device works by slowly releasing a drug called fluocinolone acetonide directly into the eye over an extended period of time, often lasting up to thirty months. By providing a steady, low-dose delivery of medicine, Retisert helps to control long-term inflammation without the need for frequent eye injections or systemic steroid pills that can affect the entire body. Because it is a localized treatment, it aims to reduce the symptoms of uveitis while minimizing some of the side effects associated with oral medications.

Copay & patient assistance

Patient Copay Amount: Not Publicly Available
Maximum Annual Benefit Limit: Not Publicly Available
Core Eligibility Restrictions: Eligible patients must have commercial insurance. Additional terms and conditions apply as specified on the Focus On Access (FOA) enrollment form.
RxBIN, PCN, and Group numbers: Not Publicly Available

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

Cost Plus Drug Company

Mark Cuban's transparent-pricing pharmacy — manufacturer cost + 15% markup + $5 dispensing fee. No insurance needed. Search alphabetically for Fluocinolone Acetonide.

Browse Cost Plus medications →

GoodRx

Compare local pharmacy prices with GoodRx coupons. Use the price with your insurance or without — whichever is cheaper.

Lookup Retisert →

NeedyMeds

Independent nonprofit directory of patient assistance programs, copay cards, and charity co-pay foundations.

Search for Fluocinolone Acetonide →

RxAssist

PAP directory maintained by Volunteers in Health Care at Brown University. Free, no ads.

Search PAPs →

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for Retisert. Official source: DailyMed (NLM) · Label effective Jul 3, 2025

Indications and usage

INDICATIONS AND USAGE Fluocinolone Acetonide Topical Solution is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Dosage and administration

DOSAGE AND ADMINISTRATION Fluocinolone Acetonide Solution is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion. Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Contraindications

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Adverse reactions

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Burning Perioral dermatitis Itching Allergic contact dermatitis Irritation Maceration of the skin Dryness Secondary infection Folliculitis Skin atrophy Hypertrichosis Striae Acneiform eruptions Miliaria Hypopigmentation

Use in pregnancy

Pregnancy Category C Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Prior authorization & coverage

Payer	PA	Step therapy	Copay tier
— Medicare Part D	—	—	—

Payer

Step therapy

Copay tier

—

Medicare Part D

—

Related drugs

How this page is sourced

Drug identity verified against openFDA NDC Directory.
Label text (when shown) originates from NLM DailyMed.
Copay and assistance URLs verified periodically; if you hit a broken link, tell us.

Rare-disease navigation (specialists, trials, patient communities)

Retisert treats a rare condition. For in-depth disease pages on our sister site:

UniteRare · Uveitis

UniteRare.org is our sister site for rare-disease navigation — same editorial team, same accuracy standards.